The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Final overall survival (OS) analysis of PHEREXA: A randomized phase III trial of trastuzumab (H) + capecitabine (X) ± pertuzumab (P) in patients with HER2-positive metastatic breast cancer (MBC) who experienced disease progression during or after H-based therapy.
 
Ander Urruticoechea
Consulting or Advisory Role - Eisai; Proacta
Travel, Accommodations, Expenses - Amgen; Proacta
 
Mohammed Rizwanullah
No Relationships to Disclose
 
Seock-Ah Im
Consulting or Advisory Role - Hanmi; Novartis; Pfizer; Proacta
Research Funding - AstraZeneca
 
Antonio Carlos Sánchez Ruiz
No Relationships to Disclose
 
Istvan Lang
No Relationships to Disclose
 
Gianluca Tomasello
No Relationships to Disclose
 
Hannah Douthwaite
Employment - Roche
 
Tanja Badovinac Crnjevic
Employment - Proacta
Stock and Other Ownership Interests - Proacta
Patents, Royalties, Other Intellectual Property - Proacta
 
Sarah Heeson
Employment - Roche
Stock and Other Ownership Interests - Proacta
Patents, Royalties, Other Intellectual Property - Roche
 
Jennifer Eng-Wong
Employment - Genentech/Roche
Stock and Other Ownership Interests - Genentech/Roche
Patents, Royalties, Other Intellectual Property - Genentech/Roche
 
Montserrat Munoz
Consulting or Advisory Role - Proacta
Speakers' Bureau - Novartis
Expert Testimony - Novartis
Travel, Accommodations, Expenses - Proacta